OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 08, 2021
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
October 06, 2021
The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.
October 04, 2021
Certara’s acquisition of Pinnacle 21 grants them access to their compliance validation software.
Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.
October 01, 2021
AstraZeneca’s acquisition of Caelum Biosciences gives them access to CAEL-101, a promising light chain amyloidosis treatment.
Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.
Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.
September 23, 2021
Boehringer Ingelheim to develop novel cancer therapies by leveraging Abexxa’s breakthrough antibody-based drugs.
September 22, 2021
Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.
September 17, 2021
Democrats failed to gain sufficient support to advance long-debated legislation to permit Medicare drug price negotiations.